title: Antiplatelet therapy for atherosclerotic disorders.
abstract: Recent studies have revealed the important roles of platelets in atherogenesis via vascular injury. Our in vivo and in vitro studies clearly demonstrate that activated platelets directly inflict injury to vascular endothelial cells, which is associated with a decrease in intracellular cyclic AMP levels in vascular tissues. Antiplatelet therapy is clinically important not only for the prevention of thrombotic episodes but also for the prevention of vascular injury and atherosclerosis. A small dose of aspirin (80 mg) induces clinically hypoaggregativeness of platelets with concomitantly decreased levels of thromboxane A2 in plasma. Our clinical study involving more than 3 years of treatment with small doses of aspirin demonstrated favorable therapeutic effects characterized by hypoaggregation of platelets and increased levels of cAMP and 6-keto PGF1 alpha in plasma which will aid in the prevention of atherosclerosis.
authors: Tokyo Medical and Dental University, Department of Internal Medicine, Japan.
authors: F
authors: F
authors: Numano
authors: Y
authors: Y
authors: Kishi
authors: T
authors: T
authors: Ashikaga
authors: T
authors: T
authors: Kobayashi
authors: K
authors: K
authors: Simokado
authors: F
authors: F
authors: Numano
authors: M
authors: M
authors: Yajima
mesh_terms: D000818:Animals; D001161:Arteriosclerosis / Q000517:prevention & control*; D004730:Endothelium, Vascular / Q000378:metabolism; D006801:Humans; D009712:Nucleotides, Cyclic / Q000378:metabolism; D015539:Platelet Activation; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*
chemical_list: D009712:Nucleotides, Cyclic; D010975:Platelet Aggregation Inhibitors